Patents by Inventor Megan Alene Cloonan FOLEY

Megan Alene Cloonan FOLEY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted indoles and methods of use thereof
    Patent number: 12116358
    Abstract: Compounds of Formula I: (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1e, G1, G2, Q1, Q2, Q3, and (II) are defined as set forth in the specification, as are uses of compounds of Formula I to treat a disease, disorder, or condition such as cancer in a subject.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: October 15, 2024
    Assignee: Epizyme, Inc.
    Inventors: John Lampe, John Campbell, Kenneth Duncan, Megan Alene Cloonan Foley, Darren Martin Harvey, Michael John Munchhof, Michael Thomenius, Lawrence Alan Reiter
  • SMYD Inhibitors
    Publication number: 20230101819
    Abstract: The present disclosure provides carboxamides and sulfonamides having Formula (I); and the pharmaceutically acceptable salts and solvates thereof, wherein A, Y, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Application
    Filed: November 22, 2021
    Publication date: March 30, 2023
    Inventors: Megan Alene Cloonan FOLEY, Kevin Wayne KUNTZ, James Edward John MILLS, Lorna Helen MITCHELL, Michael John MUNCHHOF, Darren Martin HARVEY
  • SUBSTITUTED INDOLES AND METHODS OF USE THEREOF
    Publication number: 20230075198
    Abstract: The present disclosure provides substituted indole compounds of Formula I: (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1e, G1, G2, Q1, Q2, Q3, and (II) are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disease, disorder, or condition such as cancer in a subject.
    Type: Application
    Filed: August 14, 2019
    Publication date: March 9, 2023
    Inventors: John LAMPE, John CAMPBELL, Kenneth DUNCAN, Megan Alene Cloonan FOLEY, Darren Martin HARVEY, Michael John MUNCHHOF, Michael THOMENIUS, Lawrence Alan REITER
  • SMYD INHIBITORS
    Publication number: 20210198252
    Abstract: The present disclosure provides carboxamides and sulfonamides having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, Y, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such a SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Application
    Filed: May 1, 2020
    Publication date: July 1, 2021
    Inventors: Megan Alene Cloonan Foley, Kevin Wayne KUNTZ, James Edward John MILLS, Lorna Helen MITCHELL, Michael John MUNCHHOF, Darren Martin HARVEY
  • Isoxazole carboxamides as irreversible SMYD inhibitors
    Patent number: 10669243
    Abstract: The present disclosure provides provides substituted isoxazole carboxamides having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, X, n, and m are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: June 2, 2020
    Assignee: EPIZYME, INC.
    Inventors: Richard Chesworth, Megan Alene Cloonan Foley, Kevin Wayne Kuntz, Lorna Helen Mitchell, Jennifer C. Petter, Carl Eric Schwartz
  • ISOXAZOLE CARBOXAMIDE COMPOUNDS
    Publication number: 20200148650
    Abstract: The present disclosure provides substituted isoxazole carboxamide compounds having Formula (1) and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, A, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2 Compounds of the present disclosure are especially useful for treating cancer.
    Type: Application
    Filed: September 30, 2019
    Publication date: May 14, 2020
    Inventors: Megan Alene Cloonan Foley, Kevin Wayne KUNTZ, James Edward John MILLS, Lorna Helen MITCHELL, Michael John MUNCHHOF, Darren Martin HARVEY
  • Substituted Cyclohexylamine Compounds
    Publication number: 20200123142
    Abstract: The present disclosure provides substituted cyclohexylamine compounds having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, R5, and R7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Application
    Filed: October 19, 2018
    Publication date: April 23, 2020
    Applicant: EPIZYME, INC.
    Inventors: Megan Alene Cloonan Foley, Kevin Wayne Kuntz, Lorna Helen Mitchell, Michael John Munchhof
  • SUBSTITUTED PYRROLIDINE COMPOUNDS
    Publication number: 20200102314
    Abstract: The present disclosure provides substituted pyrrolidine compounds having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein R1, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Application
    Filed: August 5, 2019
    Publication date: April 2, 2020
    Applicant: EPIZYME, INC.
    Inventors: Megan Alene Cloonan Foley, Kevin Wayne Kuntz, Lorna Helen Mitchell, Michael John Munchhof, Darren Martin Harvey
  • Substituted piperidine compounds
    Patent number: 10577363
    Abstract: The present disclosure provides substituted piperidine compounds having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: March 3, 2020
    Assignee: EPIZYME, INC.
    Inventors: Lorna Helen Mitchell, Andrew Simon Bell, Richard Chesworth, Megan Alene Cloonan Foley, Kevin Wayne Kuntz, James Edward John Mills, Michael John Munchhof
  • SUBSTITUTED PYRROLIDINE CARBOXAMIDE COMPOUNDS
    Publication number: 20200048195
    Abstract: The present disclosure provides pyrrolidine carboxamide compounds having Formula I and the pharmaceutically acceptable salts and solvates thereof, wherein A, B, X, Y, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Application
    Filed: May 28, 2019
    Publication date: February 13, 2020
    Inventors: Megan Alene Cloonan Foley, Kevin Wayne KUNTZ, Lorna Helen MITCHELL, Michael John MUNCHHOF, Darren Martin HARVEY
  • SMYD INHIBITORS
    Publication number: 20190322660
    Abstract: The present disclosure provides carboxamides and sulfonamides having Formula (I): and the pharmacentically acceptable salts and solvates thereof, wherein A, Y, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Application
    Filed: February 6, 2019
    Publication date: October 24, 2019
    Inventors: Megan Alene Cloonan Foley, Kevin Wayne Kuntz, James Edward John Mills, Lorna Helen Mitchell, Michael John Munchhof, Darren Martin Harvey
  • Isoxazole carboxamide compounds
    Patent number: 10428029
    Abstract: The present disclosure provides substituted isoxazole carboxamide compounds having Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, A, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: October 1, 2019
    Assignee: EPIZYME, INC.
    Inventors: Megan Alene Cloonan Foley, Kevin Wayne Kuntz, James Edward John Mills, Lorna Helen Mitchell, Michael John Munchhof, Darren Martin Harvey
  • Isoxazole Carboxamides as Irreversible SMYD Inhibitors
    Publication number: 20190241529
    Abstract: The present disclosure provides provides substituted isoxazole carboxamides having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, X, n, and m are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Application
    Filed: January 11, 2019
    Publication date: August 8, 2019
    Applicant: EPIZYME, INC.
    Inventors: Richard Chesworth, Megan Alene Cloonan Foley, Kevin Wayne Kuntz, Lorna Helen Mitchell, Jennifer C. Petter, Carl Eric Schwartz
  • Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer
    Patent number: 10266526
    Abstract: The present disclosure provides carboxamides and sulfonamides having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, Y, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: April 23, 2019
    Assignee: EPIZYME, INC.
    Inventors: Megan Alene Cloonan Foley, Kevin Wayne Kuntz, James Edward John Mills, Lorna Helen Mitchell, Michael John Munchhof, Darren Martin Harvey
  • Isoxazole carboxamides as irreversible SMYD inhibitors
    Patent number: 10179773
    Abstract: The present disclosure provides substituted isoxazole carboxamides having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, X, n, and m are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: January 15, 2019
    Assignee: EPIZYME, INC.
    Inventors: Richard Chesworth, Megan Alene Cloonan Foley, Kevin Wayne Kuntz, Lorna Helen Mitchell, Jennifer C. Petter, Carl Eric Schwartz
  • Substituted isoxazoles for treating cancer
    Patent number: 10106510
    Abstract: The present disclosure provides substituted cyclohexylamine compounds having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, R5, and R7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: October 23, 2018
    Assignee: EPIZYME, INC.
    Inventors: Megan Alene Cloonan Foley, Kevin Wayne Kuntz, Lorna Helen Mitchell, Michael John Munchhof
  • Isoxazole Carboxamides as Irreversible SMYD Inhibitors
    Publication number: 20180230110
    Abstract: The present disclosure provides substituted isoxazole carboxamides having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, X, n, and m are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Application
    Filed: September 9, 2015
    Publication date: August 16, 2018
    Applicant: EPIZYME, INC.
    Inventors: Richard CHESWORTH, Megan Alene Cloonan FOLEY, Kevin Wayne KUNTZ, Lorna Helen MITCHELL, Russell C. PETTER, Carl Eric SCHWARTZ
  • Substituted Piperidine Compounds
    Publication number: 20170362217
    Abstract: The present disclosure provides substituted piperidine compounds having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Application
    Filed: September 9, 2015
    Publication date: December 21, 2017
    Applicant: EPIZYME, INC.
    Inventors: Lorna Helen MITCHELL, Andrew Simon BELL, Richard CHESWORTH, Megan Alene Cloonan FOLEY, Kevin Wayne KUNTZ, James Edward John MILLS, Michael John MUNCHHOF
  • Substituted Cyclohexylamine Compounds
    Publication number: 20170362191
    Abstract: The present disclosure provides substituted cyclohexylamine compounds having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, R5, and R7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Application
    Filed: September 9, 2015
    Publication date: December 21, 2017
    Applicant: EPIZYME, INC.
    Inventors: Megan Alene Cloonan FOLEY, Kevin Wayne KUNTZ, Lorna Helen MITCHELL, Michael John MUNCHHOF
  • SMYD Inhibitors
    Publication number: 20170355695
    Abstract: The present disclosure provides carboxamides and sulfonamides having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, Y, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Application
    Filed: September 9, 2015
    Publication date: December 14, 2017
    Applicant: EPIZYME, INC.
    Inventors: Megan Alene Cloonan FOLEY, Kevin Wayne KUNTZ, James Edward John MILLS, Lorna Helen MITCHELL, Michael John MUNCHHOF, Darren Martin HARVEY